|Day Low/High||114.66 / 118.08|
|52 Wk Low/High||35.83 / 120.99|
More Detailed Poster Presentation Scheduled for April 25, 2017 at AAN Annual Meeting
- New Phase 3 Data in Lennox-Gastaut Syndrome Selected for Inclusion in the Emerging Science Program -
This innovative biotech offers investors an intriguing play on the medical marijuana business.
In the first quarter of the year we've seen some high-profile IPOs. But they're not all created equal. Here's what investors should keep an eye out for ... and avoid.
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AMRK, AXTA, DFT, GWPH, LBRDK, LBTYA, RPM Downgrades: CIEN, CRNT, IMO, SUNW, TG, TRIB, USCR Initiations: FBIO Read on to get TheStreet Quant Ratings' detailed report:
This economy is finally strong enough that a rate hike is natural and necessary, says Jim Cramer.
Jim Cramer's bullish on Burlington Stores, Ross Stores and TJX Companies.
The woes of anti-marijuana Attorney General Jeff Sessions are fueling speculative pot stock buying. But you should avoid these two high flying small fry.
President Trump's socially conservative administration has vowed to crack down on marijuana, but here's why pot investors shouldn't worry.
We talk with an industry expert about the outlook of the marijuana industry.
The applications for the company's proprietary treatments seem endless. How can investors get in, and what are the alternative pot profit-makers?
Cannabis stocks are not affected by the volatility in prices during earnings season and instead trade on positive data such as potential FDA approval on their pipeline of drugs.
Growth is almost guaranteed in these two areas, says James McDonald of Index Strategy Advisors.
Cramer is taking Magellan Midstream Partners over EQT Midstream and is waiting for Ionis Pharmaceuticals to go lower.
Going into earnings what the market needs now is more negativity, Cramer says.
Adam Feuerstein compiles a list of questions, thoughts, declarations, catalysts and observations about biotech stocks to help investors prepare for the year ahead.
The Canadian marijuana market is poised for growth as the number of registered patients continues grows and as licensed producers find innovative ways to create value for its shareholders.
GW Pharmaceuticals has developed cannabis-based therapies for treating epilepsy and multiple sclerosis.
Stocks enjoyed another strong day on Wall Street as the financial sector pushed the S&P 500 higher.